Variability of linezolid concentrations after standard dosing in critically ill patients: A prospective observational study

Critical Care

Volumn 18, Issue 4, 2014, Pages

  Zoller, Michael ^a   Maier, Barbara ^a   Hornuss, Cyrill ^a   Neugebauer, Christina ^a   Döbbeler, Gundula ^a   Nagel, Dorothea ^a   Holdt, Lesca M ^a   Bruegel, Mathias ^a   Weig, Thomas ^a   Grabein, Béatrice ^a   Frey, Lorenz ^a   Teupser, Daniel ^a   Vogeser, Michael ^a   Zander, Johannes ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; APACHE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SEPSIS; TANDEM MASS SPECTROMETRY; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; DOSE RESPONSE; INTENSIVE CARE UNIT; MIDDLE AGED; TRENDS; VERY ELDERLY;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; OXAZOLIDINONES; PROSPECTIVE STUDIES;

EID: 84905389045     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13984     Document Type: Article

References (55)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
2. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007, 33:606-618.
3. Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, Ala-Kokko TI, Kolho E, Rintala EM. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 2007, 33:435-443.
4. Martin CM, Priestap F, Fisher H, Fowler RA, Heyland DK, Keenan SP, Longo CJ, Morrison T, Bentley D, Antman N, . STAR Registry Investigators A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry. Crit Care Med 2009, 37:81-88. STAR Registry Investigators.
5. Quenot JP, Binquet C, Kara F, Martinet O, Ganster F, Navellou JC, Castelain V, Barraud D, Cousson J, Louis G, Perez P, Kuteifan K, Noirot A, Badie J, Mezher C, Lessire H, Pavon A. The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit Care 2013, 17:R65.
6. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
7. Sandiumenge A, Diaz E, Bodi M, Rello J. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003, 29:876-883.
8. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44:1009-1034.
9. Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Grundling M, John S, Kern W, Kreymann G, Krüger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stüber F, Weiler N, Weimann A, Werdan K, Welte T, et al. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinare Vereinigung fur Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci 2010, 8:Doc14.
10. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, . Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup.
11. Winterboer TM, Lecci KA, Olsen KM. Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients. Pharm Pract 2010, 23:6-18.
12. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
13. Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). Braz J Infect Dis 2009, 13:90-98.
14. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006, 12:16-23.
15. Rybak MJ, Akins RL. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs 2001, 61:1-7.
16. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, Taylor L, Hayman S, Shaw S, Kibbler C, Shulman R, Singer M, Wilson AP. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. Antimicrob Chemother 2004, 53:345-355.
17. Arakawa Y, Ike Y, Nagasawa M, Shibata N, Doi Y, Shibayama K, Yagi T, Kurata T. Trends in antimicrobial-drug resistance in Japan. Emerg Infect Dis 2000, 6:572-575.
18. Alvarez-Lerma F, Palomar Martinez M, Olaechea Astigarraga P, Insausti Ordenana J, Lopez Pueyo MJ, Gracia Arnillas MP, Gimeno Costa R, Seijas Betolaza I. Analysis of treatments used in infections caused by gram-positive multiresistant cocci in critically ill patients admitted to the ICU. Rev Esp Quimioter 2012, 25:65-73.
19. DeRyke CA, Lodise TP, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005, 128:1414-1422.
20. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008, 8:53-66.
21. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011, 66:25-31.
22. Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis 2013, 32:1121-1128.
23. Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet 2010, 49:439-447.
24. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011, 66:7-15.
25. Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, Shobe EM. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab Dispos 2001, 29:1136-1145.
26. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010, 54:4605-4610.
27. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003, 42:1129-1140.
28. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001, 45:1843-1846.
29. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003, 51:17-25.
30. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292.
31. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003, 42:1411-1423.
32. Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, Schentag JJ. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003, 14:795-801.
33. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009, 59:59-74.
34. Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, Fucile S, Gulisano C, Rizzardini G, Clementi E. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents 2013, 41:586-589.
35. Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C, MacGowan A, Shaw S, Kibbler C, Singer M, Wilson AP. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005, 55:333-340.
36. Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011, 38:296-300.
37. Morata L, Cuesta M, Rojas JF, Rodriguez S, Brunet M, Casals G, Cobos N, Hernandez C, Martinez JA, Mensa J, Soriano A. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemother 2013, 57:1913-1917.
38. Yagi T, Naito T, Doi M, Nagura O, Yamada T, Maekawa M, Sato S, Kawakami J. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients. Int J Antimicrob Agents 2013, 42:329-334.
39. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008, 31:122-129.
40. Boselli E, Breilh D, Rimmele T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005, 33:1529-1533.
41. Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010, 66:291-298.
42. De Rosa FG, Corcione S, Baietto L, Ariaudo A, Di Perri G, Ranieri VM, D'Avolio A. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents 2013, 41:590-591.
43. Bodmann KF, Grabein B. Empfehlungen zur kalkulierten parenteralen Intitialtherapie bakterieller Erkrankungen bei Erwachsenen. Update 2010. Chemotherapy J 2010, 19:179-255.
44. Zander J, Maier B, Zoller M, Teupser D, Vogeser M. Quantification of linezolid in serum by LC-MS/MS using semi-automated sample preparation and isotope dilution internal standardization. Clin Chem Lab Med 2013, 52:381-389.
45. Varvel JR, Donoho DL, Shafer SL. Measuring the predictive performance of computer-controlled infusion pumps. J Pharmacokinet Biopharm 1992, 20:63-94.
46. PLT Tools, a graphical interface for the NONMEM system. [http://www.pltsoft.com].
47. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagn Microbiol Infect Dis 2013, 76:206-213.
48. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother 2013, 57:1077-1081.
49. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012, 67:2034-2042.
50. Carcelero E, Soy D, Guerrero L, Poch E, Fernandez J, Castro P, Ribas J. Linezolid pharmacokinetics in patients with acute renal failure undergoing continuous venovenous hemodiafiltration. J Clin Pharmacol 2012, 52:1430-1435.
51. Meyer B, Kornek GV, Nikfardjam M, Karth GD, Heinz G, Locker GJ, Jaeger W, Thalhammer F. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 2005, 56:172-179.
52. Pea F, Viale P, Lugano M, Pavan F, Scudeller L, Della Rocca G, Furlanut M. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis 2004, 44:1097-1102.
53. Fiaccadori E, Maggiore U, Rotelli C, Giacosa R, Parenti E, Picetti E, Sagripanti S, Manini P, Andreoli R, Cabassi A. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004, 32:2437-2442.
54. Stokvis E, Rosing H, Beijnen JH. Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?. Rapid Commun Mass Spectrom 2005, 19:401-407.
55. Kumar A. An alternate pathophysiologic paradigm of sepsis and septic shock: Implications for optimizing antimicrobial therapy. Virulence 2013, 5:80-97.